Articles related to REAL-WORLD EVIDENCE

In a retrospective VA cohort of 669 mCRPC patients who did not progress on initial docetaxel, rechallenge with docetaxel was associated with improved overall survival compared with cabazitaxel after inverse probability of treatment weighting, though short follow-up and inherent selection pressures limit interpretation.

GLP-1 receptor agonist use was associated with a 41% lower overall risk of obesity-related cancers in a retrospective cohort of more than 229,000 non-diabetic patients with obesity, with the largest risk reductions observed in endometrial, pancreatic, colorectal, and multiple myeloma.

A retrospective analysis of more than 840,000 patients with breast cancer found lower all-cause mortality and reduced recurrence risk among those with obesity or type 2 diabetes who received GLP-1 receptor agonists compared with similar patients who did not, though the study did not establish causation.

A retrospective cohort study of 349,168 propensity-matched patients with diabetes found a hazard ratio of 2.22 for nonarteritic anterior ischemic optic neuropathy among semaglutide users compared with non-GLP-1 RA antidiabetic therapy users, with elevated risk emerging at two years and persisting through four years of follow-up.

Opioid prescribing for cancer patients reporting no pain declined substantially across a single Connecticut health system from 2016 to 2020, while prescribing for patients reporting pain remained stable.

Bariatric surgery volumes peaked in 2022 and have fallen since, with sleeve gastrectomy losing ground and Roux-en-Y conversions climbing as GLP-1 prescriptions expand.